Clinical trialPhase 2Completed
FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
BrUOG 318: FOLFOX-A For Locally Advanced Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
- Outcome
- Results posted; single-arm, no comparison
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 12 July 2016
- Ended
- 16 March 2022
- Enrollment
- 28 participants
- Sites
- 1
- Primary outcomes
- Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer.
- Sponsor type
- Academic / other
- Results posted
- 13 August 2021
- Last update
- 6 May 2023
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 6 May 2023
- Primary outcome
- Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer.Complete Response: FOLFOXA: 0 of 28Partial Response: FOLFOXA: 12 of 28Stable Disease: FOLFOXA: 12 of 28Progressive Disease: FOLFOXA: 4 of 28Values: ParticipantsTime frame: From date of start of treatment, until the date of first documented progression, whichever came first, assessed up to 3 yearsNo analysis posted for this outcome (outcome 1)
- Participants
- FOLFOXA: 28 started, 28 completed
- Serious adverse events
- FOLFOXA: 8 of 28Participants with at least one serious adverse event, of those at risk, as posted
1 secondary outcome
- OS · Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With F…
- FOLFOXA 12.3 (2 to 36), n=28 [mean months, Full Range]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Preliminary data suggests that FOLFOX-A may have equal or superior activity as compared to FOLFIRINOX for patients with metastatic pancreatic cancer and appears to be better tolerated with the ability to administer at least 10 cycles of therapy. Investigators therefore will evaluate FOLFOX-A in a phase II study for patient with locally advanced pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
See summary above
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Response Rate of FOLFOX-A for Patients With Locally Advanced Pancreatic Cancer. [From date of start of treatment, until the date of first documented progression, whichever came first, assessed up to 3 years]. Count Of Participants, Participants. Complete Response: FOLFOXA (n=28): 0. Partial Response: FOLFOXA (n=28): 12. Stable Disease: FOLFOXA (n=28): 12. Progressive Disease: FOLFOXA (n=28): 4.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival for Patients With Locally Advanced Pancreatic Cancer Treated With FOLFOX-A [During treatment (approximately every 2 weeks for up to 6 months), then approximately every 4 months for for a maximum of 5 years]. Mean, months (Full Range). FOLFOXA (n=28): 12.3 (2 to 36).